Drug | Trial | Design | Treatment | Duration | TTR (%) | Patients | Mean CHAD2 Score | Efficacy/Outcome | Safety/Outcome |
---|---|---|---|---|---|---|---|---|---|
Dabigatran | RE-LY | Blinded | VKA/dabigatran (150 mg bid) | 24 months | 64 | 18,113 patients with nonvalvular Afib | 2.1 | Stroke or systemic emboli, 1.11% Dabigatran 1.69% VKA group | Major bleeding in 2.71% Dabigatran in 3.36% of VKA group |
Rivaroxaban | Rocket AF | DB | VKA/rivaroxaban (20 mg daily) | 30 months | 55 | 14,264 patients with nonvalvular Afib | 3.5 | Stroke or systemic emboli 1.7% rivaroxaban 2.2% VKA group | Major bleeding: 3.6% in rivaroxaban group, 3.4% in VKA group |
X-Vert | DB | VKA/rivaroxaban (20 mg daily) | Months | 55 | 1504 patients needed cardioversion for Afib | 3.2 | Stroke or systemic emboli: 0.5% in rivaroxaban group and 1.02 in the VKA group | Major bleeding: 0.61% in rivaroxaban group vs 0.8% in VKA group | |
Apixaban | AVVEROUS | DB | ASA/apixaban 5 mg bid or 2.5 mg bid | 13 months | 62 | 5,599 patients with nonvalvular Afib could not take warfarin | 2.1 | Stroke or systemic emboli: 1.6% in apixaban group vs 3.7% in the ASA group | Major bleeding: 1.4% in apixaban group vs 1.2% in ASA group |
ARISTOTLE | DB | VKA/apixaban 5 mg bid or 2.5 mg bid | 22 months | 62 | 18,201 patients with nonvalvular Afib | 2.1 | Stroke or systemic emboli 1.27% apixaban 1.6% VKA group | Major bleeding 2.1 apixaban 3.09% VKA group | |
Edoxaban | ENGAGE-TIMI 48 | DB | VKA/edoxaban 60 mg daily and 30 mg daily | 34 months | 64 | 21,105 patients with nonvalvular Afib | 2.8 | Stroke or systemic emboli: 1.18% in edoxaban group vs 1.5% in VKA group | Major bleeding: 2.75% in edoxaban group vs 3.43% in VKA group |
Afib, atrial fibrillation; ASA, aspirin; DB, double blind; TTR, time in therapeutic range; VKA, Vitamin K antagonist.